At the same time, Achaogen also sort the approval of pla- zomicin (4) to treat bloodstream infection (BSI), but the FDA indicated further trials would be required to demonstrate its effectiveness. Achaogen had submitted an marketing authorization application (MAA) in October 2018 with The ...
These bacteria are resistant to the groups of antibiotics that commonly are used to treat these types of infections (penicillins, cephalosporins) and to antibiotics normally reserved for more severe infections (eg, fluoroquinolones, gentamicin). Enterobacterales are inferred to produce ESBL enzymes when...
Several studies have confirmed the emergence of resistant organisms in the faecal reservoir and urine of women who take prolonged antibiotics [11, 12]. The resistance pattern observed was not confined to the prescribed antibiotic but to a range of other antibiotic agents commonly used to treat ...
The severity of infections and the frequent resistance in ICU-acquired infections, as well as the numerous pathophysiological specificities related to the critical care setting, make the conduct of beta-lactam treatment in critical care patients challenging. However, sepsis and septic shock require the ...
This study aimed to evaluate the in vitro activity of meropenem-vaborbactam (MVB) against a collection of carbapenem-resistant Escherichia coli (CREC) isolates and to compare the activity with other antibiotics with regard to different separation sites, carba penem-resistant mechanisms, and seque...
The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR) bacteria, especially Gram-negative (G−ve) pathogens, is acknowledged as one of the world’s most pressing health issues; however, the discovery and development of new, nontoxic antibacterials is not a...
agents that bind to the PBPs inhibiting the bacterial cell wall synthesis. They show less resistance than other beta-lactams because of their stability to hydrolysis by many extended-spectrum chromosomal and plasmid-mediated beta-lactamases, including AmpC and extended-spectrum beta-lactamases (ESBLs...
Once administrated to the animal, a big part of the antibiotic is metabolized for the purpose of detoxification and excretion. In general, most of the parent product and its metabolites are excreted in urine and, to a lesser extent, via faeces. However, part of the drug may persist for a...
Susceptibility profiles of Gram-negative bacteria that produced ESBL, AmpC, and carbapenemases were similar to the expected profiles, with some differences in the response to cefepime of ESBL-producing microorganisms. Coloration values did not differ from those described by the manufacturer of ChromID ...
In fact, with the exception of Proteus mirabilis and Morganella morganii, plazomicin was found to be more effective than the other investigated aminoglycosides against ESBL-producing Escherichia coli, ESBL-producing Klebsiella pneumoniae, carbapenem-resistant Enterobacteriaceae (CRE), and colistin-resistant...